Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.38 |
| ▸ | USP1 | O94782 | 6/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371666 | 0.88 | JAK2 (0.44) | ADORA2AADORA1JAK2JAK3MAP4K1 | |
| SCHEMBL13608362 | 0.88 | ADORA2A (0.51) | ADORA2AADORA1JAK2JAK3USP1 | |
| SCHEMBL13620251 | 0.87 | JAK2 (0.43) | ADORA2AADORA1JAK2JAK3TLR7 | |
| SCHEMBL12371755 | 0.83 | ADORA2A (0.46) | ADORA2AADORA1JAK2JAK3TLR7 | |
| SCHEMBL13608364 | 0.82 | JAK2 (0.46) | ADORA2AADORA1JAK2JAK3TLR7 | |
| SCHEMBL13620430 | 0.81 | QPCT (0.43) | JAK2JAK3 | |
| SCHEMBL12371732 | 0.79 | ADORA2A (0.42) | ADORA2AADORA1JAK2JAK3TLR7 | |
| SCHEMBL13620291 | 0.79 | USP1 (0.41) | ADORA2AADORA1TLR7USP1SYK | |
| SCHEMBL12371634 | 0.79 | ADORA2A (0.42) | ADORA2AADORA1JAK2JAK3MAP4K1 | |
| SCHEMBL12371644 | 0.79 | ADORA2A (0.42) | ADORA2AADORA1JAK2JAK3MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | ADORA2A 975/4885ADORA1 1091/4885JAK2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.